Trust linked to Corcept (NASDAQ: CORT) director sells 10,000 shares in plan

Rhea-AI Filing Summary

Corcept Therapeutics director James N. Wilson, through the James N. Wilson and Pamela D. Wilson Trust, sold 10,000 shares of Common Stock on June 16, 2026 in two open-market transactions under a Rule 10b5-1 trading plan adopted on March 12, 2026. The shares were sold at weighted average prices of $83.5708 and $82.6948 per share, with actual prices ranging from $82.13 to $83.935 per share. Following these sales, the trust continues to hold more than 1.09 million shares according to the filing, while two separate 2025 Grantor Retained Annuity Trusts each report indirect holdings of 200,000 shares. Wilson disclaims beneficial ownership of the trust shares except to the extent of his pecuniary interest.

Insights

Equity compensation and insider-trading analyst

Pre-planned trust sales of 10,000 Corcept shares look routine.

The filing shows entities associated with director James N. Wilson sold 10,000 Corcept Therapeutics shares through the James and Pamela Wilson Trust. These were open-market transactions coded “S”, the clearest form of discretionary selling signal in insider reports.

A key detail is that these trades were executed under a Rule 10b5-1 trading plan adopted on March 12, 2026. Such plans pre-schedule trades, reducing the informational value of their timing. The trust still holds over 1.09 million shares, so the sale represents a small fraction of its reported position.

Two additional 2025 Grantor Retained Annuity Trusts each list 200,000 indirectly held shares, highlighting broader estate-planning structures rather than concentrated selling. Wilson also disclaims beneficial ownership of the trust shares beyond his pecuniary interest, underscoring that these positions are held through separate legal entities.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($832,049)

Net Sell 4 txns

Insider WILSON JAMES N

Role null

Sold 10,000 shs ($832K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,177	$82.6948	$345K
Sale	Common Stock	5,823	$83.5708	$487K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,100,366 shares (Indirect, James N. Wilson and Pamela D. Wilson Trust)

Footnotes (1)

1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.13 to $83.125 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.16 to $83.935 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Key Figures

Shares sold: 10,000 shares Weighted average sale price 1: $83.5708/share Weighted average sale price 2: $82.6948/share +5 more

8 metrics

Shares sold 10,000 shares Total Corcept common shares sold by Wilson trust on June 16, 2026

Weighted average sale price 1 $83.5708/share First block of reported open-market sales on June 16, 2026

Weighted average sale price 2 $82.6948/share Second block of reported open-market sales on June 16, 2026

Price range block 1 $82.13–$83.125/share Actual trade prices for first sale block, per footnote

Price range block 2 $83.16–$83.935/share Actual trade prices for second sale block, per footnote

Trust holdings after sales >1.09 million shares Approximate Corcept shares held by James and Pamela Wilson Trust post-transaction

Pamela 2025 GRAT holdings 200,000 shares Indirect Corcept holdings in Pamela D. Wilson 2025 Grantor Retained Annuity Trust

James 2025 GRAT holdings 200,000 shares Indirect Corcept holdings in James N. Wilson 2025 Grantor Retained Annuity Trust

Key Terms

Rule 10b5-1 trading plan, Grantor Retained Annuity Trust, beneficial ownership, weighted average sale price, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Grantor Retained Annuity Trust financial

"Pamela D. Wilson 2025 Grantor Retained Annuity Trust"

A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.

beneficial ownership regulatory

"disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

weighted average sale price financial

"Represents the weighted average sale price for the entire number of shares sold."

open-market sale market

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILSON JAMES N

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2026		S(1)		4,177	D	$82.6948(2)	1,100,366	I	James N. Wilson and Pamela D. Wilson Trust(4)
Common Stock	06/16/2026		S(1)		5,823	D	$83.5708(3)	1,094,543	I	James N. Wilson and Pamela D. Wilson Trust(4)
Common Stock								200,000	I	James N. Wilson 2025 Grantor Retained Annuity Trust
Common Stock								200,000	I	Pamela D. Wilson 2025 Grantor Retained Annuity Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.13 to $83.125 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.16 to $83.935 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for James N. Wilson	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)